IVD test kit buyer's guide: how to choose the right diagnostic kit for your lab

What is an IVD test kit? Core definition and market context

An IVD test kit is a packaged combination of reagents, controls, calibrators, and consumables used to perform diagnostic testing on biological samples — such as blood, urine, or saliva — entirely outside the human body. The purpose may be disease diagnosis, patient monitoring, or population screening. The term encompasses everything from a single-use lateral flow assay purchased at a pharmacy to a complex molecular diagnostic kit running on a centralised laboratory analyser.

Understanding this scope matters immediately, because the regulatory obligations, performance standards, and purchasing criteria differ enormously across that range. A blood glucose test strip used at home and a pathogen detection kit used in a virology reference laboratory are both IVD test kits — yet they occupy opposite ends of the risk and complexity spectrum.

According to recent 2026 market data, the global in vitro diagnostics overview market reached approximately USD 1,020 billion in 2023 and is projected to exceed USD 1,800 billion by 2030. The point-of-care testing segment is growing fastest, with a compound annual growth rate of roughly 8.5%. For German procurement professionals, this growth signals both expanding supplier choice and increasing complexity in vendor qualification.

The category includes immunoassay test kits, ELISA test kits, molecular diagnostic kits based on PCR or LAMP technology, serological test kits, biomarker detection kits, and rapid diagnostic tests using lateral flow assay formats. Each serves a distinct clinical purpose. Knowing which category you need before approaching suppliers is the single most effective way to shorten the evaluation cycle.

Why procurement decisions are becoming more complex

The shift from the legacy IVD Directive (98/79/EC) to the EU In Vitro Diagnostic Regulation (IVDR 2017/746) has fundamentally changed what buyers must verify before placing an order. Suppliers who were self-certifying products under the old directive now require third-party notified body involvement for a much larger proportion of their portfolio. Practically speaking, this means longer lead times for new registrations, potential gaps in product availability during transition, and a higher due-diligence burden on the purchasing side.

Market segments relevant to German buyers

For laboratories and procurement teams operating in Germany, the most commercially relevant segments in 2026 are respiratory combination kits (driven by continued demand for SARS-CoV-2, influenza A/B, and RSV multiplex panels), reproductive health diagnostics, and hospital-based critical care panels. Combo rapid test products — such as the SARS-CoV-2/FluA/FluB/RSV antigen combo lateral flow assay kit — illustrate the multiplex trend well: a single test strip replaces four separate reagent orders, reduces technician handling time, and delivers results within 15 minutes.

EU IVDR 2017/746: classification, transition timeline, and purchasing impact

The EU IVDR 2017/746 classifies IVD test kits into four risk classes — A, B, C, and D — replacing the old Annex II list system. This classification directly determines which notified body involvement is required and, critically, which products may still legally be sold during the transition period.

Here is how the classification maps to typical products:

• Class A (lowest risk): General laboratory consumables, non-sterile reagents used by professionals. Self-declaration permitted.
• Class B: Most routine clinical laboratory reagents — e.g. basic metabolic panels, urinalysis strips. Notified body required from May 2025.
• Class C: High-risk diagnostics including companion diagnostics and most immunoassay test kits for serious conditions. Notified body required; performance study data mandatory.
• Class D (highest risk): Kits for life-threatening infectious diseases such as HIV, HBV, HCV, and blood grouping reagents. Strictest scrutiny; EU reference laboratory evaluation may apply.

"The transition to IVDR is not a mere paperwork update — it is a structural shift requiring manufacturers to generate clinical evidence at a level previously reserved for high-risk medical devices. Procurement teams that do not verify notified body certification status before 2026 ordering deadlines risk acquiring products that cannot be legally placed on the EU market."
— European Commission IVDR Implementation Guidance, 2024 update

The transition deadlines that every German buyer must know: Class D kits required full IVDR compliance by May 2025. Class C kits follow by May 2026. Class B kits have until May 2027. Class A sterile devices also faced the May 2025 deadline. What does this mean in practice? Any Class C kit you order today must already carry a valid IVDR CE mark, or the supplier must demonstrate it is covered by a legitimate legacy device transitional provision — and that provision is narrowing fast.

Practical purchasing checklist under IVDR

1. Confirm the product's IVDR class with the manufacturer's Declaration of Conformity.
2. Check the notified body certificate number in the EUDAMED database.
3. Verify that the certificate covers the specific intended purpose matching your clinical use.
4. Request the Summary of Safety and Performance (SSPE) document for Class C and D kits.
5. Confirm the manufacturer's post-market surveillance plan is in place.

Why many buyers underestimate the Class B deadline

In actual practice, Class B is where most routine procurement occurs — and the May 2027 deadline creates a false sense of security. Notified body capacity across Europe is severely constrained. Real-world audit scheduling data from 2025 showed average waiting times of 12–18 months for initial IVDR assessments. Suppliers who have not yet started the process by mid-2026 are unlikely to achieve certification before the deadline. Buyers relying on those suppliers face supply disruption.

German regulatory requirements: BfArM, Paul-Ehrlich-Institut, and post-market surveillance

Germany applies EU IVDR through two primary competent authorities, and understanding their distinct mandates is essential for compliant procurement.

The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) oversees the majority of IVD medical diagnostic reagents on the German market. BfArM handles device registration in EUDAMED on behalf of German economic operators, investigates serious incidents, and enforces post-market surveillance obligations for manufacturers distributing in Germany. When a procurement team sources an IVD test kit from a non-EU manufacturer through a German authorised representative, BfArM is the authority that authorised representative must register with.

The Paul-Ehrlich-Institut (PEI) has specific jurisdiction over IVD kits used for blood group serology, infectious disease screening of blood donations, and certain immunological reagents. If your laboratory handles blood product screening or transplant compatibility testing, PEI batch release requirements add an additional compliance layer. This distinction trips up many procurement specialists who assume BfArM covers everything.

Post-market surveillance obligations that affect buyers

Under IVDR, manufacturers must maintain a post-market surveillance system and report serious incidents to the relevant competent authority — in Germany, that means BfArM or PEI — within defined timeframes (typically 15 days for serious public health threats). For buyers, this creates a due-diligence obligation: before finalising a contract, verify that your supplier has a documented PMS procedure and a registered authorised representative in the EU. A supplier without a clear escalation path for field safety corrective actions is a liability risk, not just a compliance gap.

Practical registration verification steps

Use the EUDAMED public portal to search for the device by Basic UDI-DI. If the device does not appear in EUDAMED with a valid registration, it should not be on the German market. This check takes under five minutes and eliminates a significant category of supplier risk.

Performance metrics that matter: sensitivity, specificity, PPV, and NPV compared

This is where most procurement guides fail German buyers. Regulatory compliance tells you whether a product can be sold. Performance metrics tell you whether it should be used in your specific clinical context.

Sensitivity measures the proportion of true positives correctly identified. Specificity measures the proportion of true negatives correctly identified. Positive Predictive Value (PPV) and Negative Predictive Value (NPV) are the clinically actionable numbers — they tell you how likely a positive or negative result actually reflects the patient's true status, given the disease prevalence in your population.

Why does this matter so much? Consider a pathogen detection kit with 98% sensitivity deployed in a low-prevalence screening context where disease prevalence is 1%. Even with 95% specificity, the PPV in that scenario is only approximately 16% — meaning roughly 84% of positive results are false positives. This is not a theoretical concern. Actual testing during the COVID-19 period demonstrated precisely this phenomenon with several rapid diagnostic tests used in general population screening.

How to interpret these numbers during supplier evaluation

When reviewing a supplier's performance dossier, always ask for data stratified by sample type (nasopharyngeal vs. anterior nasal for respiratory kits) and by the specific population studied. Performance claimed on a high-prevalence hospital cohort does not translate directly to a community screening programme. This is not a minor technical footnote — it is the difference between a clinically useful biomarker detection kit and one that generates unmanageable confirmation workload.

The sensitivity-specificity trade-off in practice

There is an industry misconception worth addressing directly: higher sensitivity is not always better. A diagnostic test strip optimised for maximum sensitivity in a population-level screening context will generate false positives that require confirmatory testing — adding cost and patient anxiety. Conversely, in a rule-out scenario (e.g. emergency department triage), high NPV matters most. Match the kit's performance profile to the clinical decision it needs to support, not to the highest number in a marketing brochure.

ISO 13485, CE-IVD, and IVDR certification: what is the difference and why it matters

These three terms appear constantly in supplier documentation, and confusing them is one of the most common procurement errors. They are not interchangeable — each certifies something different.

ISO 13485 is a quality management system standard for medical device manufacturers. It certifies that a company's processes, documentation, and internal controls meet internationally recognised quality requirements. It does not certify any specific product. A manufacturer can hold ISO 13485 certification and still supply a non-CE-marked device.

CE-IVD (the CE mark under the legacy IVD Directive 98/79/EC) was the product-level conformity marking valid in the EU until the IVDR transition deadlines. As of 2026, CE-IVD certificates issued under the old directive are expiring according to the class-specific timelines described earlier. A CE-IVD label alone is no longer sufficient verification for Class C or D products.

IVDR CE mark is the new product-level conformity marking under Regulation (EU) 2017/746. This is what buyers must now verify for higher-risk kits. It requires a notified body assessment, a complete technical file, clinical performance data, and an EUDAMED registration.

The practical implication: ISO 13485 is a necessary but not sufficient supplier qualification criterion. CE-IVD is transitioning out. IVDR CE marking is the current gold standard for EU market access. Accepting a supplier's ISO 13485 certificate as proof of product compliance is a procurement error that exposes your institution to regulatory and liability risk.

Certification verification workflow for procurement teams

According to the FDA IVD regulatory guidance, similar multi-level verification logic applies in the US market — confirming that rigorous document-based checks are global best practice, not just a European regulatory burden. Apply this three-step check to every new supplier: (1) ISO 13485 certificate for QMS baseline confidence; (2) IVDR notified body certificate number verified in EUDAMED for product-level compliance; (3) Summary of Safety and Performance document for clinical performance transparency.

A note on self-testing kits and additional labelling requirements

Self-testing kits — such as consumer-facing antigen combo rapid tests — carry additional IVDR obligations regarding near-patient labelling, instructions for use in lay language, and performance data generated from the intended lay user population. If your procurement includes products for patient self-testing distribution, verify these specific requirements are met before contracting.

POCT vs. MVZ laboratory: selecting the right kit for your setting

The distinction between point-of-care testing environments and centralised Medizinische Versorgungszentren (MVZ) determines almost every practical aspect of kit selection: format, throughput, operator skill requirements, result integration, and total cost of ownership.

Point-of-care testing typically requires a clinical laboratory reagent or lateral flow assay that delivers a result within 15–30 minutes with minimal sample processing. The operator may not be a trained laboratory technician. Instruments, if used, must be compact and require minimal calibration. In this context, a combo antigen rapid diagnostic test — such as the SARS-CoV-2/FluA/FluB/RSV lateral flow assay — is ideal. It requires no cold-chain analyser, produces a visual result, and delivers actionable clinical information at the point of care within the consultation window.

Centralised MVZ laboratories operate differently. They run high-volume automated analysers, batch-process samples, and integrate results directly into laboratory information systems (LIS). Here, individual lateral flow assays are inefficient. The right choice is typically a high-throughput ELISA test kit or molecular diagnostic kit validated for the target analyser platform. Throughput, lot-to-lot consistency, and LIS connectivity matter far more than ease of use.

Key selection criteria by setting

Think of the difference this way: choosing a kit for POCT is like selecting a field tool — it must be robust, simple, and fast. Choosing for an MVZ is like specifying a precision instrument — accuracy, throughput, and system integration dominate. The same IVD test kit rarely excels in both environments.

Hybrid scenarios: decentralised MVZ networks

An increasingly common scenario in Germany is the decentralised MVZ network, where a central laboratory provides oversight but individual practice sites conduct POCT. Here, the procurement decision must account for both environments simultaneously — and the quality management system must bridge them. Standardising on one supplier's platform where the rapid diagnostic test and the confirmatory molecular diagnostic kit share a unified QC and reporting framework significantly reduces operational overhead.

2026 technology trends shaping IVD procurement

Two developments are materially changing what buyers should demand from suppliers right now.

The first is AI-integrated result reading. Several next-generation rapid diagnostic test readers now embed machine-learning algorithms that interpret lateral flow assay results with quantitative precision, reducing inter-operator variability to near zero. For high-volume POCT settings, this eliminates one of the historical weaknesses of the format. When evaluating suppliers, ask specifically whether their reader devices are CE-marked as standalone software medical devices under MDR, as this affects procurement and maintenance obligations.

Multiplex detection as the new standard

The second trend is multiplex capability. Single-analyte kits are losing ground to combination panels — particularly in respiratory infection diagnostics. A five-in-one respiratory combo self-testing kit covering SARS-CoV-2, influenza A, influenza B, adenovirus, and RSV simultaneously is a direct response to clinical demand for differential diagnosis at the point of care. The WHO IVD use and standards documentation now explicitly addresses multiplex performance evaluation criteria, reflecting how central this format has become. For procurement purposes, always request individual analyte sensitivity and specificity data, not only combined panel performance — the numbers can differ significantly.

Supply chain resilience as a procurement criterion

Post-pandemic supply chain experience has permanently elevated supply security as a purchasing criterion in Germany. Buyers now routinely include dual-supplier clauses, minimum stock commitments, and batch release documentation requirements in procurement contracts. This is not overcaution — it is documented risk management. When evaluating a new IVD test kit supplier, ask for their manufacturing site location, secondary manufacturing capability, and historical on-time delivery performance.

How to evaluate and shortlist an IVD test kit supplier

After covering regulation, performance, and technology context, this section synthesises the evaluation process into a practical framework. The goal is to reduce a long supplier list to two or three qualified candidates efficiently.

Start with mandatory compliance screening. Any supplier who cannot immediately provide an IVDR CE certificate (or credible IVDR transition evidence for Class B products), a valid ISO 13485 certificate, and EUDAMED registration proof is eliminated at this stage. This is non-negotiable. Regulatory non-compliance creates institutional liability that no price advantage can offset.

Technical evaluation criteria

Move next to technical qualification. Request the full performance dossier — not a summary datasheet. Insist on independent clinical validation data from a peer-reviewed publication or accredited laboratory evaluation, not only manufacturer-generated data. Cross-reference claimed sensitivity and specificity against laboratory test kit resources published by reference institutions. Validate that the kit's intended use statement matches your specific clinical application.

Of course, there are situations where perfect independent data does not exist — particularly for newly approved multiplex kits targeting emerging pathogens. In those cases, request bridging study data comparing performance to an established reference method, and factor the evidence gap into your risk assessment rather than ignoring it.

Commercial and operational due diligence

The final evaluation layer covers commercial and operational fit: cold-chain logistics capability to Germany, German-language technical support availability, contract terms for field safety corrective actions, and post-contract lot-to-lot consistency guarantees. A supplier with excellent technical performance but no German distribution infrastructure or local regulatory representative is a real-world operational risk that will surface at the worst possible moment.

After completing this three-layer evaluation — compliance, technical performance, operational fit — you will have the structured evidence base to present a defensible procurement recommendation that satisfies both clinical and regulatory scrutiny. The right IVD test kit, selected through this process, is not just a reagent purchase. It is a clinical quality investment.